Lu Wang
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 11
- Co-authors
- Hao Zhang (12 shared papers)Hui‐Chuan Sun (6 shared papers)Wei‐Zhong Wu (4 shared papers)Zhao–You Tang (3 shared papers)Xiao Xiong (8 shared papers)Peng–Yuan Zhuang (2 shared papers)Huaxiang Xu (2 shared papers)Ling–Qun Kong (2 shared papers)
- Journals
- Clinical Cancer Research (3 papers)Cancer Letters (3 papers)Journal of Medicinal Chemistry (3 papers)Cancer Management and Research (2 papers)Acta Pharmacologica Sinica (2 papers)
- Partner nations
- ChinaUnited StatesNetherlands
In The Last Decade
Lu Wang
141 papers receiving 3.9k citations
Lu Wang's Hit Papers
Peers
Comparison fields: 5 of 134
- Cancer Research 372
- Oncology 607
- Drug Discovery 7
- Hepatology 193
- Biological Psychiatry 29
Countries citing papers authored by Lu Wang
This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).
Fields of papers citing papers by Lu Wang
This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 153 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial Hit paper breakdown → | 2021 | 359 |
| 2 | 2010 | 345 | |
| 3 | 2019 | 202 | |
| 4 | 2022 | 159 | |
| 5 | 2014 | 149 | |
| 6 | 2016 | 134 | |
| 7 | 2020 | 132 | |
| 8 | 2013 | 93 | |
| 9 | Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3 Hit paper breakdown → | 2024 | 90 |
| 10 | 2011 | 83 | |
| 11 | 2017 | 76 | |
| 12 | 2005 | 75 | |
| 13 | 2018 | 72 | |
| 14 | 2006 | 71 | |
| 15 | 2016 | 71 | |
| 16 | 2016 | 63 | |
| 17 | 2012 | 62 | |
| 18 | 2013 | 60 | |
| 19 | 2023 | 51 | |
| 20 | 2003 | 49 |
About Lu Wang
Lu Wang is a scholar working on Oncology, Cancer Research, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 153 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Inflammasome and immune disorders (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Medical Imaging Techniques and Applications (7 papers), Angiogenesis and VEGF in Cancer (7 papers), Esophageal Cancer Research and Treatment (6 papers), Extracellular vesicles in disease (6 papers) and Freshwater macroinvertebrate diversity and ecology (5 papers). The work is most often cited by research in Cancer Research (372 citations), Oncology (607 citations), Drug Discovery (7 citations), Hepatology (193 citations) and Biological Psychiatry (29 citations). Lu Wang has collaborated with scholars based in China, United States and Netherlands. Frequent co-authors include Hao Zhang, Hui‐Chuan Sun, Wei‐Zhong Wu, Zhao–You Tang, Xiao Xiong, Peng–Yuan Zhuang, Huaxiang Xu, Ling–Qun Kong, Xiao‐Dong Zhu and Yuquan Xiong. Their work appears in journals such as Clinical Cancer Research, Cancer Letters, Journal of Medicinal Chemistry, Cancer Management and Research and Acta Pharmacologica Sinica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.